Caitlin Marie Dugdale, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 17 | 2024 | 17533 | 1.060 |
Why?
|
| Trichomonas Infections | 1 | 2022 | 41 | 0.770 |
Why?
|
| Infectious Disease Transmission, Vertical | 6 | 2023 | 1354 | 0.760 |
Why?
|
| Anthozoa | 1 | 2021 | 65 | 0.730 |
Why?
|
| Syphilis | 1 | 2024 | 243 | 0.720 |
Why?
|
| Patient Isolation | 1 | 2020 | 101 | 0.660 |
Why?
|
| Infant Care | 2 | 2020 | 181 | 0.630 |
Why?
|
| Chlamydia Infections | 1 | 2022 | 364 | 0.610 |
Why?
|
| Masks | 1 | 2020 | 209 | 0.590 |
Why?
|
| Gonorrhea | 1 | 2022 | 354 | 0.570 |
Why?
|
| Benzoxazines | 1 | 2019 | 320 | 0.560 |
Why?
|
| Postnatal Care | 1 | 2019 | 275 | 0.550 |
Why?
|
| Whipple Disease | 1 | 2016 | 20 | 0.540 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 295 | 0.520 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2022 | 667 | 0.510 |
Why?
|
| Cost-Benefit Analysis | 6 | 2023 | 5526 | 0.460 |
Why?
|
| Coxiella burnetii | 1 | 2014 | 37 | 0.440 |
Why?
|
| Fever of Unknown Origin | 1 | 2014 | 94 | 0.440 |
Why?
|
| Community Pharmacy Services | 1 | 2014 | 51 | 0.440 |
Why?
|
| Q Fever | 1 | 2014 | 38 | 0.440 |
Why?
|
| Endophthalmitis | 1 | 2016 | 263 | 0.430 |
Why?
|
| Endocarditis | 1 | 2016 | 350 | 0.390 |
Why?
|
| Pharmacists | 1 | 2014 | 260 | 0.380 |
Why?
|
| Africa South of the Sahara | 3 | 2024 | 751 | 0.380 |
Why?
|
| Nucleic Acid Amplification Techniques | 2 | 2021 | 335 | 0.300 |
Why?
|
| South Africa | 4 | 2022 | 1867 | 0.280 |
Why?
|
| Anti-Retroviral Agents | 3 | 2023 | 1787 | 0.270 |
Why?
|
| Cote d'Ivoire | 2 | 2023 | 65 | 0.260 |
Why?
|
| HIV-1 | 1 | 2023 | 6944 | 0.240 |
Why?
|
| Prevalence | 6 | 2024 | 15842 | 0.230 |
Why?
|
| Mass Screening | 2 | 2021 | 5446 | 0.210 |
Why?
|
| Communicable Diseases | 2 | 2021 | 874 | 0.210 |
Why?
|
| Erythema | 1 | 2023 | 262 | 0.190 |
Why?
|
| Pregnancy | 8 | 2023 | 30260 | 0.170 |
Why?
|
| Physicians | 3 | 2022 | 4588 | 0.160 |
Why?
|
| Eye | 1 | 2023 | 710 | 0.160 |
Why?
|
| Infant | 7 | 2023 | 36386 | 0.160 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2019 | 1899 | 0.150 |
Why?
|
| Alkynes | 1 | 2019 | 326 | 0.150 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2020 | 164 | 0.150 |
Why?
|
| Cyclopropanes | 1 | 2019 | 437 | 0.140 |
Why?
|
| Eye Diseases | 1 | 2023 | 659 | 0.140 |
Why?
|
| Oxazines | 1 | 2019 | 358 | 0.130 |
Why?
|
| Neural Tube Defects | 1 | 2019 | 256 | 0.130 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2021 | 790 | 0.130 |
Why?
|
| Epididymitis | 1 | 2016 | 37 | 0.130 |
Why?
|
| Orchitis | 1 | 2016 | 36 | 0.130 |
Why?
|
| Models, Economic | 1 | 2020 | 716 | 0.130 |
Why?
|
| Humans | 30 | 2024 | 765968 | 0.130 |
Why?
|
| HIV Antibodies | 1 | 2023 | 1337 | 0.130 |
Why?
|
| Perinatal Care | 1 | 2018 | 246 | 0.120 |
Why?
|
| Medical Tourism | 1 | 2016 | 51 | 0.120 |
Why?
|
| Ceftriaxone | 1 | 2016 | 176 | 0.120 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2021 | 2587 | 0.120 |
Why?
|
| Anti-HIV Agents | 2 | 2021 | 4559 | 0.120 |
Why?
|
| Education, Pharmacy, Continuing | 1 | 2014 | 3 | 0.120 |
Why?
|
| Animals, Domestic | 1 | 2014 | 55 | 0.120 |
Why?
|
| Infant, Newborn | 4 | 2023 | 26346 | 0.110 |
Why?
|
| Neurocysticercosis | 1 | 2015 | 88 | 0.110 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2021 | 2187 | 0.110 |
Why?
|
| Disease Reservoirs | 1 | 2014 | 124 | 0.110 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 856 | 0.110 |
Why?
|
| Radiography, Thoracic | 1 | 2020 | 1315 | 0.110 |
Why?
|
| Pyridones | 1 | 2019 | 816 | 0.110 |
Why?
|
| Adult | 13 | 2024 | 223044 | 0.110 |
Why?
|
| Transaminases | 1 | 2014 | 199 | 0.110 |
Why?
|
| Myositis | 1 | 2016 | 270 | 0.110 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 1175 | 0.110 |
Why?
|
| Zoonoses | 1 | 2014 | 181 | 0.110 |
Why?
|
| Child | 7 | 2023 | 80564 | 0.100 |
Why?
|
| Cerebral Ventricles | 1 | 2015 | 549 | 0.100 |
Why?
|
| Hepatitis | 1 | 2014 | 227 | 0.100 |
Why?
|
| Female | 14 | 2024 | 396112 | 0.100 |
Why?
|
| Granuloma | 1 | 2014 | 327 | 0.100 |
Why?
|
| Tachycardia | 1 | 2014 | 594 | 0.100 |
Why?
|
| Inhalation Exposure | 1 | 2014 | 432 | 0.090 |
Why?
|
| Nausea | 1 | 2014 | 680 | 0.090 |
Why?
|
| Professional Role | 1 | 2014 | 313 | 0.090 |
Why?
|
| Arthritis | 1 | 2016 | 677 | 0.090 |
Why?
|
| Vomiting | 1 | 2014 | 647 | 0.090 |
Why?
|
| Zimbabwe | 2 | 2022 | 135 | 0.090 |
Why?
|
| HIV | 3 | 2022 | 1585 | 0.080 |
Why?
|
| Point-of-Care Systems | 1 | 2019 | 1217 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 2780 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2021 | 9649 | 0.080 |
Why?
|
| Surgery, Plastic | 1 | 2016 | 651 | 0.080 |
Why?
|
| Male | 11 | 2024 | 363698 | 0.080 |
Why?
|
| Piperazines | 1 | 2019 | 2549 | 0.080 |
Why?
|
| Boston | 1 | 2020 | 9338 | 0.070 |
Why?
|
| Hospitals | 1 | 2020 | 3888 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2019 | 3564 | 0.070 |
Why?
|
| Brain Diseases | 1 | 2015 | 1546 | 0.070 |
Why?
|
| Headache | 1 | 2014 | 1259 | 0.060 |
Why?
|
| Counseling | 1 | 2014 | 1551 | 0.060 |
Why?
|
| Incidence | 2 | 2021 | 21480 | 0.060 |
Why?
|
| Software | 1 | 2019 | 4462 | 0.060 |
Why?
|
| Young Adult | 4 | 2020 | 59889 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 2024 | 0.060 |
Why?
|
| Adolescent | 4 | 2022 | 88835 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2019 | 5089 | 0.060 |
Why?
|
| Early Diagnosis | 2 | 2021 | 1187 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2022 | 42500 | 0.060 |
Why?
|
| Bone Marrow | 1 | 2014 | 2921 | 0.060 |
Why?
|
| Pandemics | 2 | 2020 | 8703 | 0.050 |
Why?
|
| Isoindoles | 1 | 2022 | 35 | 0.050 |
Why?
|
| Trifluridine | 1 | 2022 | 27 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3100 | 0.050 |
Why?
|
| Monkeypox virus | 1 | 2022 | 43 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3223 | 0.050 |
Why?
|
| Biopsy | 1 | 2014 | 6763 | 0.050 |
Why?
|
| Lung | 1 | 2020 | 10033 | 0.050 |
Why?
|
| Breast Feeding | 2 | 2020 | 1364 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 7478 | 0.050 |
Why?
|
| Hospitalization | 1 | 2020 | 10808 | 0.040 |
Why?
|
| Health Policy | 2 | 2021 | 2698 | 0.040 |
Why?
|
| Liver | 1 | 2014 | 7562 | 0.040 |
Why?
|
| Mozambique | 1 | 2018 | 55 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 6547 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2023 | 81514 | 0.040 |
Why?
|
| United States | 4 | 2022 | 72903 | 0.040 |
Why?
|
| Community Health Centers | 1 | 2021 | 469 | 0.030 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2020 | 618 | 0.030 |
Why?
|
| Immunization | 1 | 2021 | 1219 | 0.030 |
Why?
|
| Animals | 2 | 2021 | 168764 | 0.030 |
Why?
|
| Middle Aged | 3 | 2020 | 223009 | 0.030 |
Why?
|
| Guatemala | 1 | 2015 | 161 | 0.030 |
Why?
|
| Rhode Island | 1 | 2015 | 351 | 0.030 |
Why?
|
| Drug Resistance, Viral | 1 | 2020 | 866 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2020 | 1668 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2021 | 1737 | 0.030 |
Why?
|
| Meningitis | 1 | 2015 | 216 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2016 | 15747 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2020 | 1205 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2022 | 1759 | 0.030 |
Why?
|
| RNA | 1 | 2023 | 2717 | 0.030 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 5370 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2019 | 1247 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2018 | 1432 | 0.020 |
Why?
|
| Drainage | 1 | 2016 | 1179 | 0.020 |
Why?
|
| Radiography | 1 | 2020 | 6919 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2023 | 41649 | 0.020 |
Why?
|
| Emigrants and Immigrants | 1 | 2015 | 549 | 0.020 |
Why?
|
| Rural Population | 1 | 2018 | 2317 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 10070 | 0.020 |
Why?
|
| Genotype | 1 | 2020 | 13024 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2019 | 6255 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2022 | 4873 | 0.020 |
Why?
|
| Models, Biological | 1 | 2021 | 9443 | 0.010 |
Why?
|
| Developing Countries | 1 | 2016 | 2911 | 0.010 |
Why?
|
| Quality Improvement | 1 | 2018 | 3853 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 15880 | 0.010 |
Why?
|
| Research Design | 1 | 2018 | 6209 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 10383 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 12976 | 0.010 |
Why?
|
| Risk Factors | 1 | 2023 | 74840 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 59489 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2019 | 65188 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 36532 | 0.000 |
Why?
|
| Aged | 1 | 2020 | 171117 | 0.000 |
Why?
|